• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Rejuvenation Technologies

Monday, June 03, 2024
CP
Regenerative Medicine
Rejuvenation Technologies is extending telomeres using telomerase RNA to treat age-related diseases. Our pipeline includes respiratory, hepatic, and hematopoietic deficiency indications. We recently received over $5M in grants including a $4M grant from the California Institute of Regenerative Medicine (CIRM) to extend telomeres to treat pulmonary fibrosis. Since being launched from Stanford University the founders have developed highly efficient and well-tolerated delivery vehicles for delivering mRNA and circular RNA to extra-hepatic targets. We are on track to begin clinical trials in 2025.
Rejuvenation Technologies
Company Website: http://rejuvenationtech.com
Lead Product in Development: RNA/LNP biologics to extend telomeres to treat pulmonary fibrosis, liver disease, hematopoietic deficiency respectively
Number Of Unlicensed Products (For Which You Are Seeking Partners): 3

Website

http://rejuvenationtech.com

Company HQ City

Mountain View

Company HQ State

CA

Company HQ Country

United States

CEO/Top Company Official

John Ramunas

Lead Product in Development

RNA/LNP biologics to extend telomeres to treat pulmonary fibrosis, liver disease, hematopoietic deficiency respectively

Development Phase of Primary Product

Pre-Clinical
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS